https://www.creative-biolabs.com/nash-therapy/nash-target-development-service-for-leukotriene-receptor-antagonists.htm Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is thought to become the leading liver disease worldwide currently. Leukotriene receptor is regarded as a potential target since it is involved in the NASH occurrence. Creative Biolabs is a pioneer company in providing target identification for drug discovery services. Our professional scientists are committed to the identification of potential drug targets research, and now we can provide high-quality leukotriene receptor antagonists for the treatment of NASH. Our experienced scientists will take part in every step of your program to accelerate your project development. With the help of our professional scientists, we are confident in providing NASH-associated services to meet every customer's requirements.
Creative Biolabs was founded by scientists who are dedicated to the conquering of cancer. We believe to build up a custom-service-centered business model is important for optimizing the drug development process, leveraging accessible resources, and forming a team of various background to conduct drug discovery in future. Our commitment to this long-term goal motivates us to deliver the highest quality results to our clients with speed.